178 related articles for article (PubMed ID: 15270644)
1. TRICOM: enhanced vaccines as anticancer therapy.
Levy B; Panicalli D; Marshall J
Expert Rev Vaccines; 2004 Aug; 3(4):397-402. PubMed ID: 15270644
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J
J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691
[TBL] [Abstract][Full Text] [Related]
3. Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
Morse MA
Curr Opin Mol Ther; 2001 Aug; 3(4):407-12. PubMed ID: 11525565
[TBL] [Abstract][Full Text] [Related]
4. [New advances in clinical trials of cancer vaccines].
Peng F; Wei YQ
Ai Zheng; 2006 Aug; 25(8):1059-62. PubMed ID: 16965694
[TBL] [Abstract][Full Text] [Related]
5. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Morse MA; Clay TM; Hobeika AC; Osada T; Khan S; Chui S; Niedzwiecki D; Panicali D; Schlom J; Lyerly HK
Clin Cancer Res; 2005 Apr; 11(8):3017-24. PubMed ID: 15837756
[TBL] [Abstract][Full Text] [Related]
7. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
Slavin-Chiorini DC; Catalfamo M; Kudo-Saito C; Hodge JW; Schlom J; Sabzevari H
Cancer Gene Ther; 2004 Oct; 11(10):665-80. PubMed ID: 15354200
[TBL] [Abstract][Full Text] [Related]
8. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
[TBL] [Abstract][Full Text] [Related]
9. Development of the PANVAC-VF vaccine for pancreatic cancer.
Petrulio CA; Kaufman HL
Expert Rev Vaccines; 2006 Feb; 5(1):9-19. PubMed ID: 16451103
[TBL] [Abstract][Full Text] [Related]
10. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
11. A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors.
Ahlers CM; Camphausen K; Citrin D; Arlen PM; Gulley JL
Clin Colorectal Cancer; 2006 May; 6(1):72-5. PubMed ID: 16796796
[No Abstract] [Full Text] [Related]
12. Pox viral vaccine approaches.
Arlen PM; Kaufman HL; DiPaola RS
Semin Oncol; 2005 Dec; 32(6):549-55. PubMed ID: 16338420
[TBL] [Abstract][Full Text] [Related]
13. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J
J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review.
Berinstein NL
J Clin Oncol; 2002 Apr; 20(8):2197-207. PubMed ID: 11956282
[TBL] [Abstract][Full Text] [Related]
15. The next generation of vaccines for the treatment of cancer.
Long L; Glover RT; Kaufman HL
Curr Opin Mol Ther; 1999 Feb; 1(1):57-63. PubMed ID: 11249685
[No Abstract] [Full Text] [Related]
16. TRICOM vector based cancer vaccines.
Garnett CT; Greiner JW; Tsang KY; Kudo-Saito C; Grosenbach DW; Chakraborty M; Gulley JL; Arlen PM; Schlom J; Hodge JW
Curr Pharm Des; 2006; 12(3):351-61. PubMed ID: 16454749
[TBL] [Abstract][Full Text] [Related]
17. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
van der Burg SH; Bijker MS; Welters MJ; Offringa R; Melief CJ
Adv Drug Deliv Rev; 2006 Oct; 58(8):916-30. PubMed ID: 16979788
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen as a target for cancer vaccines.
Hodge JW
Cancer Immunol Immunother; 1996 Nov; 43(3):127-34. PubMed ID: 9001565
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Gulley JL; Arlen PM; Tsang KY; Yokokawa J; Palena C; Poole DJ; Remondo C; Cereda V; Jones JL; Pazdur MP; Higgins JP; Hodge JW; Steinberg SM; Kotz H; Dahut WL; Schlom J
Clin Cancer Res; 2008 May; 14(10):3060-9. PubMed ID: 18483372
[TBL] [Abstract][Full Text] [Related]
20. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
Doehn C; Kausch I; Böhmer T; Sommerauer M; Jocham D
Curr Opin Mol Ther; 2007 Apr; 9(2):183-9. PubMed ID: 17458173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
